imrecoxib and Pain--Postoperative

Imrecoxib, a novel cyclooxygenase-2 inhibitor, possesses a certain postoperative analgesic effect for several orthopedic surgeries. This multi-center, randomized, controlled, non-inferiority study intended to investigate the postoperative analgesic efficacy and safety profile of imrecoxib (versus celecoxib) in hip osteoarthritis patients undergoing total hip arthroplasty (THA).. 156 hip osteoarthritis patients planned for THA were randomized into imrecoxib (N = 78) and celecoxib (N = 78) groups. Patients were orally administrated with imrecoxib or celecoxib 200 mg at 2 h (h) after THA, 200 mg every 12 h to day (D)3, and 200 mg every 24 h to D7; additionally, each patient received patient-controlled analgesia (PCA) for 2 days.. Resting pain visual analogue scale (VAS) score at 6 h, 12 h, D1, D2, D3, and D7 post THA was not varied between imrecoxib and celecoxib groups (all P > 0.050), neither was moving pain VAS score (all P > 0.050). Importantly, the upper of 95% confidence interval of pain VAS score margin between imrecoxib and celecoxib groups was within the non-inferiority threshold (Δ = 1.0), indicating the fact that non-inferiority was established. The additional and total consumption of PCA was not varied between imrecoxib and celecoxib groups (both P > 0.050). Also, no difference was seen in Harris hip score, European Quality of Life 5-Dimensions (EQ-5D) total and VAS scores at month (M)1, M3 between the two groups (all P > 0.050). Besides, the incidences of all adverse events were not different between imrecoxib and celecoxib groups (all P > 0.050).. Imrecoxib is non-inferior to celecoxib for postoperative analgesia in hip osteoarthritis patients undergoing THA.

Topics: Analgesics; Arthroplasty, Replacement, Hip; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Humans; Osteoarthritis, Hip; Pain, Postoperative; Quality of Life

To investigate the relationship between the vertical distance from semitendinosus insertion to tibial plateau (S-T) and the physical characteristics of patients, in order to provide reference for incision design to expose the semitendinosus insertion.. The patients with ligament injury who underwent primary anterior cruciate ligament reconstruction between January 2022 and December 2022 were selected as the research subjects. The patients' baseline data were collected, including age, gender, height, and body mass. During reconstruction operation, the S-T was measured. Considering the S-T as the dependent variable and baseline data as the independent variable, multiple linear regression analysis was used to establish a regression equation to determine the possible influencing factors of semitendinosus insertion location.. There was a linear relationship between the height and semitendinosus insertion. The location of semitendinosus insertion estimated by the formula (S-T=-14.701+0.407×height) is reasonable, which provides a theoretical basis for rapid, accurate, and safe location of semitendinosus insertion and design of surgical incision in clinic.. 探讨半腱肌止点至胫骨平台垂直距离（S-T）与患者体格特征间的关系，为临床设计半腱肌止点切口提供参考。.. 以2022年1月—12月接受初次前交叉韧带重建治疗的韧带损伤患者为研究对象。收集患者基线资料，包括年龄、性别、身高、体质量，在韧带重建术中测量S-T。以S-T为因变量、患者基线资料为自变量，行多重线性回归分析并建立回归方程，判断半腱肌止点位置影响因素。.. 患者身高与半腱肌止点位置存在线性关系，通过公式S-T=−14.701+0.407×身高可估计半腱肌止点位置，为临床快速、准确、安全定位半腱肌止点，设计手术切口提供参考。.. 探讨艾瑞昔布超前镇痛方案在前交叉韧带（anterior cruciate ligament，ACL）重建术后镇痛的效果。.. 选取2020年11月—2021年8月收治且符合选择标准的ACL损伤患者160例，按照随机数字表法分为4组，每组40例。A组术前3 d开始服用艾瑞昔布（100 mg/次，2次/d）；B组术前1 d开始服用艾瑞昔布（100 mg/次，2次/d）；C组术前2 h服用200 mg艾瑞昔布，5 mL水顿服；D组术前不服用任何止痛药物。4组患者性别、年龄、身体质量指数、术前半月板损伤MRI分级≥3级构成比、软骨损伤Outerbridge分级≥3级构成比及术前受伤时和静息时疼痛视觉模拟评分（VAS）等基线资料比较，差异均无统计学意义（. 所有患者均完成1年随访，4组患者手术时间、住院时间、围术期ASA 1级构成比比较差异均无统计学意义（. 与传统镇痛方案比较，ACL重建围术期应用艾瑞昔布超前镇痛理念管理，能够有效减轻患者术后早期疼痛，减少阿片类药物使用量，促进患者肢体功能尽早恢复。.

Topics: Analgesia; Analgesics, Opioid; Anterior Cruciate Ligament Reconstruction; Correlation of Data; Female; Hamstring Muscles; Humans; Knee Injuries; Male; Osteoarthritis, Knee; Pain, Postoperative; Physical Examination; Plastic Surgery Procedures; Quality of Life

Imrecoxib is a novel cyclooxygenase-2 inhibitor independently developed in China, which exhibits a good efficacy and tolerance in orthopedic disorders. The current study aimed to further compare its efficacy and safety with celecoxib as postoperative analgesia in arthroscopic knee surgery (AKS).. Patients receiving AKS were enrolled and randomly assigned to imrecoxib (n = 64) and celecoxib (n = 62) group to receive analgesia for 72 h after surgery. Pain at rest and movement, pethidine consumption, patient's satisfaction, Lysholm score, and adverse events were assessed after AKS. Meanwhile the upper limit of 95% CI of pain-score mean difference (MD) between imrecoxib and celecoxib was calculated, then, the non-inferiority was defined if the all-time-point upper limits of 95% CI less than 1.. Imrecoxib was non-inferior to celecoxib for alleviating pain at rest (upper limit of 95% CI of MD ranging from 0.443 to 0.782, all time-point values less than 1); as well as for attenuating pain at movement (upper limit of 95% CI of MD ranging from 0.398 to 0.582, all time-point values less than 1). Moreover, rescue analgesia rate (P = 0.583), pethidine consumption (P = 0.454), patient's satisfaction at 72 h (P = 0.408), and Lysholm score at M3 (P = 0.776) were of no difference between imrecoxib group and celecoxib group. Additionally, the main adverse events in two groups were nausea (P = 0.425), constipation (P = 1.000), vomiting (P = 0.715), headache (P = 1.000), and dizziness (P = 0.667), which were mild and manageable.. Imrecoxib is non-inferior to celecoxib in postoperative analgesia and exhibits an acceptable tolerance in patients undergoing AKS.

Topics: Analgesia; Celecoxib; Humans; Meperidine; Pain, Postoperative; Pyrroles; Sulfides